stonks4u
Sign up free
DNLI logo

DNLI Denali Therapeutics Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$24.40
-0.42 (-1.69%)

Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule i…

Market Cap: $3.87Bwww.denalitherapeutics.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

120
8093107120
Aug 10Aug 13

Quote

Day Range
$24.11 – $24.59
52-Week Range
$12.58 – $27.30
Volume
$846.2K
Market Cap
$3.87B
50-Day Avg
$23.85
200-Day Avg
$20.25
Prev Close
$24.82
Open
$24.53

Valuation & Ratios

P/E Ratio
-5.56
EPS
$-2.92
P/B Ratio
2.86
P/S Ratio
0.00
Debt/Equity
0.04
Current Ratio
9.16
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-50.6%
Return on Assets
-44.8%
FCF Yield
-14.6%
EV/EBITDA
-5.48

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-512.54M$-2.97
2024$0.00$-422.77M$-2.57
2023$330.53M$-145.22M$-1.06
2022$108.46M$-325.99M$-2.60
2021$48.66M$-290.58M$-2.39

Social Signal Score

51
5d
51
2 mentions
—
30d
51
2 mentions
—
60d
51
2 mentions
—
90d
51
2 mentions
—
news: 2

Earnings

Thu, Nov 5(in 3 months)

Consensus estimate $-0.41 per share

5of 7 quarters beat consensus

Typical surprise +2.7% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 6$-0.68 vs $-0.51miss
  • Thu, May 7$-0.69 vs $-0.73beat
  • Thu, Feb 26$-0.73 vs $-0.75beat
  • Thu, Nov 6$-0.74 vs $-0.76beat
  • Mon, Aug 11$-0.72 vs $-0.74beat
  • Tue, May 6$-0.78 vs $-0.71miss

Estimates and results for DNLI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

DNLIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (2)

  • Newsseekingalpha.com·2d ago·Positive

    Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One Denali Therapeutics (DNLI) is transitioning from a neuroscience platform to a commercial biotech with AVLAYAH, its FDA-approved rare-disease therapy. AVLAYAH's Q2 revenue of $3.6M is projected to triple in Q3, reflecting accelerating patient uptake and payer coverage progress. DNLI's TransportVehicle platform underpins a pipeline spanning enzymes, antibodies, and oligonucleotides, targeting both rare and large neurodege…

    View source ↗
  • Newsgurufocus.com·4d ago·Negative

    Baillie Gifford Trims Denali Therapeutics (DNLI) Stake in June Reduction On June 30, 2026, Baillie Gifford (Trades, Portfolio) executed a reduction of 106,249 shares in Denali Therapeutics Inc (NASDAQ: DNLI) at a traded price of $25.7

    View source ↗